吉西他滨与长春瑞滨联合顺铂治疗晚期乳腺癌的临床效果分析  

Clinical Efficacy of Gemcitabine and Navelbine Combined with Cisplatin on the Advanced Breast Cancer

作　　者：王妍[1] 刘海岭[2] 张春侠[1] 尚永健[1] 章来长[1] 

机构地区：[1]空军航空医学研究所附属医院,北京100089 [2]武警北京总队第三医院,北京100141

出　　处：《现代生物医学进展》2015年第4期676-678,共3页Progress in Modern Biomedicine

摘　　要：目的:探讨吉西他滨与长春瑞滨联合顺铂治疗晚期乳腺癌的近期疗效。方法:选取2012年5月-2013年12月在我院接受治疗的晚期乳腺癌患者80例,随机分为观察组和对照组,每组40例。对照组给予吉西他滨+顺铂治疗,观察组给予长春瑞滨+顺铂治疗。比较两组患者的近期总有效率和不良反应的发生情况。结果:观察组治疗总有效率为70%,对照组为62.5%,两组临床疗效无显著差异(P>0.05);两组患者治疗后均出现不同程度的不良反应。其中,观察组患者血小板减少、白细胞减少、静脉炎、恶心呕吐及脱发等毒副反应的发生率为50%,而对照组患者毒副反应的发生率为72.5%。观察组显著低于对照组,差异具有统计学意义(P<0.05)。结论:吉西他滨与长春瑞滨联合顺铂治疗晚期乳腺癌具有显著的临床疗效,且安全性较高,值得临床应用。Objective：To investigate the efficacy of Gemcitabine combined Cisplatin and Navelbine combined Cisplatin in the treatment of advanced breast cancer.Methods：80 patients in our hospital from May 2012 to December 2013 were selected and randomly divided into the control group and the observation group with 40 cases in each group.The patients in the control group were treated with Gemcitabine combined Cisplatin.The patients in the observation group were treated with Navelbine combined Cisplatin.Then the clinical efficacy and the adverse reactions were compared between the two groups.Results：There was no statistically significant difference about the clinical efficacy between two groups（P〉0.05）.The incidence of adverse reactions in the observation group was 50% which was significantly lower than 72.5% in the control group with statistically significant differences（P〈0.05）.Conclusion：Gemcitabine and Navelbine combined with Cisplatin have better clinical efficacy on the treatment of advanced breast cancer with better efficacy and less adverse reactions.

关 键 词：吉西他滨 长春瑞滨 顺铂 晚期乳腺癌 临床疗效 

分 类 号：R737.9[医药卫生—肿瘤]